NCT03536039View on ClinicalTrials.gov

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

PHASE2CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

January 27, 2016

Primary Completion Date

January 27, 2019

Study Completion Date

January 27, 2020

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG

NGR-hTNF

dose of 0.8 mcg/sqm

OTHER

RITUXIMAB

dose of 375 mg/mq

DRUG

Doxorubicin

dose of 50 mg/mq

DRUG

Cyclophosphamide

dose of 750 mg/mq

DRUG

Vincristine

dose of 1.4 mg/mq (max 2 mg)

DRUG

Prednisone

75 mg

Trial Locations (1)

20132

Ospedale San Raffaele, Milan

Sponsors

Collaborators (1)

AGC Biologics S.p.A.

All Listed Sponsors

collaborator

AGC Biologics S.p.A.

INDUSTRY

lead

Andres J. M. Ferreri

OTHER